DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20214702

Elevation of serum E-selectin in Thai hyperlipidemia adults

Apinya Michuea, Somsak Fongsupa, Thaval Rerksngarm, Sudawadee Kongkhum

Abstract


Background: Hyperlipidemia is an important risk factor of cardiovascular diseases (CVD), whose pathogenesis involves vascular endothelial dysfunction. Therefore, a specific marker of endothelial dysfunction, serum E-selectin, was assessed in Thai hyperlipidemia adults.

Methods: Subjects who had no history of hypertension, diabetes and other serious illness were recruited and classified as normolipidemia (n=100) and hyperlipidemia (n=100), by using the levels of blood lipids (hyperlipidemia: total cholesterol >200 mg/dl, low density lipoprotein cholesterol (LDL-C) >130 mg/dl, and triglyceride >150 mg/dl). Clinical data were collected, and laboratory analysis was done. Serum levels of uric acid, fasting blood glucose (FBS), blood urea nitrogen (BUN), and creatinine were measured by the dry chemistry automate analyzer. Serum E-selectin was measured by using the enzyme-linked immunosorbent assay.

Results: The hyperlipidemia subjects had significantly higher serum E-selectin levels than the normolipidemia subjects (18.98±11.58.56 versus 8.85±4.02 ng/ml). E-selectin was significantly correlated with blood lipids; total cholesterol, triglyceride, LDL-C, and HDL-C (r=0.477, 0.441, 0.453, and -0.191, respectively). Moreover, significant correlations of E-selectin with uric acid and fasting blood glucose were also found (r=0.155 and 0.166, respectively).

Conclusions: Serum E-selectin levels increased in hyperlipidemia and correlated with uric acid and fasting blood glucose, reflecting the association between hyperlipidemia and pathogenesis of CVD, Therefore, it emphasizes the importance of hyperlipidemia management.

 


Keywords


Hyperlipidemia, E-selectin, Endothelial dysfunction

Full Text:

PDF

References


Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol 2021;18:689-700.

Aekplakorn W, Taneepanichskul S, Kessomboon P, Chongsuvivatwong V, Putwatana P, Sritara P, et al. Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. J Lipids. 2014;249584.

Adhyaru BB, Jacobson TA. New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia. Endocrinol Metab Clin North Am. 2016;45(1):17-37.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8(5):473-88.

Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-95.

Zhang Y, Thompson AM, Tong W, Xu T, Chen J, Zhao L, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China. J Hypertens. 2010;28(1):35-40.

Wu J, Liang Z, Zhou J, Zhong C, Jiang W, Zhang Y, et al. Association of Biomarkers of Inflammation and Endothelial Dysfunction with Fasting and Postload Glucose Metabolism: A Population-Based Prospective Cohort Study Among Inner Mongolians in China. Can J Diabetes. 2016;40(6):509-14.

Lee CH, Kuo FC, Tang WH, Lu CH, Su SC, Liu JS, et al. Serum E-selectin concentration is associated with risk of metabolic syndrome in females. PLoS One. 2019;14(9):e0222815.

Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev. 2019;8563845.

Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.

Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168-75.

Meigs JB, O'Donnell C J, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabete.s 2006;55(2):530-7.

Roldan V, Marin F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost. 2003;90(6):1007-20.

Eikendal ALM, Bots ML, Gohar A, Lutgens E, Hoefer IE, den Ruijter HM, et al. Circulating levels of P-selectin and E-selectin relate to cardiovascular magnetic resonance-derived aortic characteristics in young adults from the general population, a cross-sectional study. J Cardiovasc Magn Reson. 2018;20(1):54.

Tang L, Peng H, Xu T, Wang A, Wang G, Tong W, et al. Association of biomarkers of inflammation with dyslipidemia and its components among Mongolians in China. PLoS One. 2014;9(2):e89023.

Wan Ahmad WN, Sakri F, Mokhsin A, Rahman T, Mohd Nasir N, Abdul-Razak S, et al. Low serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelial activation. PLoS One. 2015;10(1):e0116867.

Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996;93(7):1334-8.

Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998;18(5):723-31.

Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, 2nd, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20(1):83-9.

Bo S, Gambino R, Durazzo M, Ghione F, Musso G, Gentile L, et al. Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. J Endocrinol Invest. 2008;31(6):499-504.

Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 2009;202(1):11-7.

Chang CC, Wu CH, Liu LK, Chou RH, Kuo CS, Huang PH, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. Sci Rep. 2018;8(1):5234.

Ghazizadeh H, Rezaei M, Avan A, Fazilati M, Pasdar A, Tavallaie S, et al. Association between serum cell adhesion molecules with hs-CRP, uric acid and VEGF genetic polymorphisms in subjects with metabolic syndrome. Mol Biol Rep. 2020;47(2):867-75.

Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129-34.

Barkas F, Elisaf M, Liberopoulos E, Liamis G, Ntzani EE, Rizos EC. Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. J Cardiol. 2019;74(3):290-5.

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263(21):2893-8.

Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, Wagenknecht LE, Karter AJ, et al. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 2013;98(4):1622-30.